You are here
Implantable cardioverter-defibrillators (ICDs) are true lifesavers, but like all devices, their components potentially can malfunction. The natural life of a well-performing ICD lead, for instance, is about 10 years or so but several models of leads have higher rates of failure. Properly managing a patient with a failing lead or a recalled lead is a clinical challenge.
The mean pregnancy-associated plasma protein A (PAPP A) levels of patients who presented with chest pain at a hospital were higher in patients who went on to have a cardiovascular event within 90 days than in patients who did not have an event.
Treating heart failure with angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and aldosterone antagonists provided the largest gains in quality-adjusted life years compared with treatments that did not include all three agents. Treatment according to guidelines resulted in an incremental cost-effectiveness ratio of less than $1,500 per quality-adjusted life year.
A bedside device that can calibrate subtle eye and head movements may be key to correctly diagnosing strokes in patients who present with dizziness, nausea, nystagmus, unsteady gait and head movement intolerance.
Combining research-derived data, practice guidance and common clinical experience, the American College of Cardiology Foundation, the Heart Rhythm Society and other specialty societies released appropriate use criteria (AUC) for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy.
Wyoming hospitals that achieve accreditation by nationally recognized accrediting bodies for care of STEMI and stroke will now receive public recognition from the Wyoming Health Department. In what an American Heart Association (AHA) official called “a great first step,” Wyoming Gov. Matt Mead signed a bill requiring the public recognition on Feb. 28.
Day-of-surgery admissions, early extubation and mobilization in pediatric surgeries to correct congenital heart defects (CHDs) reduce costs of admissions by a third, with no increase in morbidity and mortality, according to a study published online Feb. 26 in Circulation: Cardiovascular Quality and Outcomes.
Predicting atrial fibrillation (AF) risk in otherwise healthy women with no known cardiovascular disease may require only easily obtainable information that is readily available to physicians and other healthcare practitioners, according to a study published online Feb. 26 in the European Heart Journal.
EHRs lighten administrative burden, but practices must roll out implementation carefully and anticipate bumps in the road.
An administrator and two cath lab directors share tips on how to preserve good will and restore a damaged reputation.